Role of sICAM-1 and sVCAM-1 as biomarkers in early and late stages of schizophrenia
- 1 February 2016
- journal article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 73, 45-52
Abstract
No abstract availableKeywords
Funding Information
- Ministry for Science and Environmental Protection (175056, 175058)
This publication has 50 references indexed in Scilit:
- Dual destructive and protective roles of adaptive immunity in neurodegenerative disordersTranslational Neurodegeneration, 2014
- Age-dependent modifications in vascular adhesion molecules and apoptosis after 48-h reperfusion in a rat global cerebral ischemia modelAGE, 2014
- Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollariesAustralian & New Zealand Journal of Psychiatry, 2014
- A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental healthJournal of Psychiatry and Neuroscience, 2012
- An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forcesInternational Journal of Neuropsychopharmacology, 2011
- Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseasesFrontiers in Molecular Neuroscience, 2011
- Intercellular Adhesion Molecule-1 Expression Is Required on Multiple Cell Types for the Development of Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2007
- Elevation of plasma concentration of adhesion molecules in late‐life depressionInternational Journal of Geriatric Psychiatry, 2006
- Remission in Schizophrenia: Proposed Criteria and Rationale for ConsensusAmerican Journal of Psychiatry, 2005
- The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosisSchizophrenia Research, 2003